Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
55 GBX | +5.77% |
|
+4.76% | -11.29% |
Sales 2024 * | 4.75M 6.19M | Sales 2025 * | 66.09M 86.11M | Capitalization | 1.39B 1.82B |
---|---|---|---|---|---|
Net income 2024 * | -104M -136M | Net income 2025 * | -84M -109M | EV / Sales 2024 * | 293 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 21.1 x |
P/E ratio 2024 * |
-24.2
x | P/E ratio 2025 * |
-39.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma plc
1 day | +5.77% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+23.55% | 27.87B | |
-17.74% | 20.95B | |
-16.15% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- VRNA Stock
- VRP Stock